A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β2 glycoprotein I and anti-phosphatidylserine/ prothrombin autoantibodies

Modern Rheumatology

Volumn 22, Issue 5, 2012, Pages 769-773

  Hirakawa, Eri ^a   Saito, Kazuyoshi ^a   Hirata, Shintaro ^a   Atsumi, Tatsuya ^b   Koike, Takao ^b   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti cardiolipin 2 glycoprotein I (anti CL b2GPI) antibody; Anti phosphatidylserine prothrombin (anti PS PT) antibody; Catastrophic antiphospholipid antibody syndrome (CAPS)

Indexed keywords

ANTICOAGULANT AGENT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BACTERIAL ENDOCARDITIS; BRAIN INFARCTION; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; DISEASE ACTIVITY; DISEASE COURSE; ECHOCARDIOGRAPHY; FATIGUE; FEVER; HEMIPLEGIA; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY INFARCTION; LIMB WEAKNESS; LUNG EMBOLISM; LUNG INFARCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MITRAL VALVE; NUCLEAR MAGNETIC RESONANCE IMAGING; PETECHIA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SCINTIGRAPHY; SPLEEN INFARCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; VALVE; VEIN THROMBOSIS;

ADOLESCENT; ANTIBODIES, ANTICARDIOLIPIN; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CARDIOLIPINS; CATASTROPHIC ILLNESS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHOSPHATIDYLSERINES; PLASMA EXCHANGE; PROTHROMBIN; TREATMENT OUTCOME;

EID: 84870347737     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0563-z     Document Type: Article

References (17)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346(10):752-63.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
3. Cervera R, Font J, Gomez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64(8):1205-9.
4. Meroni PL, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheumatol. 2001;13(5): 377-82.
5. Vega-Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep. 2007;9(3):190-7.
6. Di Simone N, Meroni PL, D'Asta M, Di Nicuolo F, D'Alessio MC, Caruso A. Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update. 2007;13(2):189-96.
7. Yasuda S. Pathogenic roles of anti-beta2-GPI antibody in patients with antiphospholipid syndrome. Nihon Rinsho Meneki Gakkai Kaishi 2004;27(6):373-8 (in Japanese).
8. Atsumi T, Koike T. Antiprothrombin antibody: why do we need more assays? Lupus. 2010;19(4):436-9.
9. Sakai Y, Atsumi T, Ieko M, Amengual O, Furukawa S, Furusaki A, et al. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum. 2009; 60(8):2457-67.
10. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum. 2003;48(4):886-95.
11. Yasuda S, Koike T. New insights into the pathogenicity of antiphospholipid antibodies. Nihon Rinsho Meneki Gakkai Kaishi 2006;29(5):311-8 (in Japanese).
12. Szodoray P, Tarr T, Tumpek J, Kappelmayer J, Lakos G, Poor G, et al. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity. 2009;42(6):497-506.
13. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus. 2003; 12(4):302-7.
14. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies-Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost. 2004;91(5):967-76.
15. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem. 2001;47(6):1008-15.
16. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568-76.
17. Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34(2): 346-52.